Vanflyta Approved for FLT3-ITD Positive Acute Myeloid Leukemia
The FDA has approved Vanflyta (quizartinib) plus chemotherapy for adults with newly diagnosed AML that is FLT3-ITD positive.
Source: empr.com
📰 Boxed Warning News
Page 23 - Boxed Warning News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
– Key Initiatives Highlight the Role of Catalytic Collaboration to Help Advance Health Equity – – Latest HIV Research and Development Data Drive the Next Wave of Person-Centric Scientific Discovery in Treatment, Prevention and Novel Research Strategies in HIV Cure –
Source: marketscreener.com
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
Aurinia Pharmaceuticals Inc. today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the...
United States Greg Keenan Amit Saxena Aurinia Pharmaceuticals Inc Division Of Rheumatology American College Of Rheumatology
Source: marketscreener.com
Coherus and Superior Biologics Announce National
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of...
Source: globenewswire.com
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
YUSIMRY™ (adalimumab-aqvh) product image REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and…
Source: sina.com.hk
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Phase 3 TruE-AD3 Study met its primary endpoint
United States Incyte Corporation Exchange Commission Us Census Bureau Us Food Drug Administration Drug Administration
Source: marketscreener.com
REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Jul 5, 2023--
Source: cadillacnews.com
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve access and affordability for patients and the US health care system
Source: marketscreener.com
REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd)
Autoinjector recognized by the Arthritis Foundation with Ease of Use CertificationIndividualized patient support program “HADLIMA For You” available including co-pay supportDesigned to improve access and affordability for patients and the US health care systemJERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Orga...
Source: pharmiweb.com
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
–$995 per carton represents a discount of more than 85% compared to Humira® – – YUSIMRY™ meets high unmet need by providing patients, employers, physicians and payers...
United States Marek Ciszewski Coherus Biosciences Jodi Sievers Denny Lanfear Hidradenitis Suppurativa
Source: marketscreener.com